Considering the role that Mnk-eIF4E pathway plays in cancer progression and the fact that Mnk2-eIF4E is constitutively activated during gemcitabine resistance [16], we evaluated the potential of gal/analogs to abrogate Mnk-eIF4E activation in PDAC as a plausible mechanism for their efficacy in gemcitabine-resistant cells. Here, EIF4E is linked to cancer.